Divis Laboratories Ltd traded at 11,442.00 this Friday November 13th, decreasing 43.00 or 0.37 percent since the previous trading session. Looking back, over the last four weeks, Divis Laboratories Ltd lost 26.81 percent. Over the last 12 months, its price rose by 75.72 percent. Looking ahead, we forecast Divis Laboratories Ltd to be priced at 10,077.97 by the end of this quarter and at 9,384.04 in one year, according to Trading Economics global macro models projections and analysts expectations.
Divi''s Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.